"This is changing the way we practice prostate cancer." ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should justify use in earlier lines of care, one analyst said.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...